When Harper Ryals turned 2, she hit a growth spurt. But her mom, Rebecca Newman, noticed something unusual with her daughter’s growth — Harper’s fingertips had turned blue. “She got really big really ...

AUGUSTA, Ga. - A cancer drug that helps keep tumors from growing blood vessels may help patients with a rare genetic condition in which malformed vessels increase their risk for bleeding and anemia.

A drug approved for treating the blood cancer multiple myeloma may offer a safe and effective way to reduce the risk of severe nosebleeds from a rare but devastating bleeding disorder. Hereditary ...

A clinical trial of Vaderis Therapeutics' AKT inhibitor engasertib suggests it could be the first effective treatment for hereditary haemorrhagic telangiectasia (HHT), the second most common inherited ...

SAN DIEGO -- In a randomized trial, pomalidomide (Pomalyst) significantly reduced severe nosebleeds in patients with hereditary hemorrhagic telangiectasia (HHT), a condition with no approved therapy.

Patients with hereditary hemorrhagic telangiectasia (HHT), a rare genetic disorder that causes abnormal blood vessel formation, wage a lifelong battle against skin lesions, frequent nosebleeds and ...

Results demonstrate that DIAG723, the Company's lead clustering antibody, can prevent PAH, offering the potential as a first-in-class PAH treatment PAH is a progressive and life-threatening disorder ...

Intravenous bevacizumab should be considered as a first-line therapy for the treatment of refractory bleeding in patients with severe hereditary hemorrhagic telangiectasia, reports Mayo Clinic ...